What is the current status of second-line chemotherapy for castration-resistant prostate cancer?

Affiliations

Comment

Jonathan E Rosenberg et al. Nat Clin Pract Urol. 2008 Dec.

. 2008 Dec;5(12):650-1.

doi: 10.1038/ncpuro1232. Epub 2008 Oct 21.

¹ Harvard Medical School, Lank Center for Genitourinary Oncology, Dana-Farber CancerInstitute, Boston, MA 02446, USA. jonathan_rosenberg@dfci.harvard.edu

No abstract available

Comment on

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.
Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Berthold DR, et al. J Clin Oncol. 2008 Jan 10;26(2):242-5. doi: 10.1200/JCO.2007.12.4008. J Clin Oncol. 2008. PMID: 18182665 Clinical Trial.
Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa.
Berthold DR, Pond GR, de Wit R, Eisenberger M, Tannock IF; TAX 327 Investigators. Berthold DR, et al. Ann Oncol. 2008 Oct;19(10):1749-53. doi: 10.1093/annonc/mdn288. Epub 2008 May 16. Ann Oncol. 2008. PMID: 18487550 Clinical Trial.